Yes, Hualing Medicine, a brand-new mechanism diabetes drug developed by Zhangjiang Enterprise in recent 10 years, has just obtained a drug production license, which is a necessary condition for submitting a new drug listing application. At the same time, it also means that under the drug marketing license holder system, enterprises have prepared for the commercial production and supply of drugs after listing.

This drug license is clear, the name of the drug is "nexavar", the entrusted manufacturer is Desino, and it is clear that the persons in charge of quality and production are all relevant personnel of Hualing Pharmaceutical.

Extended data

The Significance of Dozza Gridin

Different from the existing drugs, "Dozza Gliadine" developed by Zhangjiang in 65,438+00 is the first drug with a brand-new mechanism in the world, which is not only a breakthrough in the research and development of new drugs in major diseases, but also a drug with this mechanism, and has established an international common name. It has conducted two phase III clinical trials in China and published very positive curative effect data.

At present, the clinical application of new drugs has entered the final sprint stage, and the drug production license is a necessary condition for submitting the application for listing, which will accelerate its application process; At the same time, it also means that Hualing and its entrusted producers have completed the core work of commercial production preparation, and can seamlessly connect production after approval.